VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Conference item |
Published: |
American Society of Clinical Oncology
2018
|